ImmuCell Corporation (ICCC) Q4 2025 Financial Results Summary

ImmuCell (ICCC) Q4 2025 Financial Results Summary

For Immediate Release: January 8, 2026

ImmuCell Corporation (Nasdaq: ICCC) has announced its preliminary, unaudited sales results for both the fourth quarter and the full year ended December 31, 2025. This announcement provides a detailed overview of the company’s performance, reflecting both successes and challenges in sales across various segments.

Q4 2025 Summary

• Total Sales: $7.6 million

• Change: 1.6% decrease compared to $7.8 million in Q4 2024.

• Domestic Sales: $7.0 million

• Change: 8.7% increase from $6.4 million in Q4 2024.

• International Sales: $0.6 million

• Change: 52.6% decrease from $1.3 million in Q4 2024.

• Tri-Shield® Sales: $6.0 million

• Change: 41.3% increase from $4.2 million in Q4 2024.

• Dual-Force® and Other Sales: $1.7 million

• Change: 53.0% decrease from $3.6 million in Q4 2024.

Full Year 2025 Summary

• Total Sales: $27.6 million

• Change: 4.3% increase compared to $26.5 million in 2024.

• Domestic Sales: $24.4 million

• Change: 6.5% increase from $22.9 million in 2024.

• International Sales: $3.3 million

• Change: 9.6% decrease from $3.6 million in 2024.

• Tri-Shield® Sales: $19.9 million

• Change: 26.5% increase from $15.8 million in 2024.

• Dual-Force® and Other Sales: $7.7 million

• Change: 28.2% decrease from $10.7 million in 2024.

Write-downs and Impairments

• During Q4 2025, ImmuCell reported several non-cash impairment write-downs:
• Re-Tain® Property, Plant and Equipment: $2.9 million
• Other Property, Plant and Equipment: $0.1 million
• Colostrum Inventory Write-down: $0.6 million
• Total Write-downs: $3.6 million

Strategic Focus

• On December 24, 2025, ImmuCell announced a realignment of its strategic focus towards expanding the First Defense® product line after receiving an Incomplete Letter from the FDA concerning Re-Tain®.

• The company plans to repurpose assets associated with Re-Tain®—worth approximately $15.5 million net book value—as part of enhancing First Defense®.

• Manufacturing improvements achieved during 2025 resulted in a year-over-year output increase of over 15%.

• A 50% expansion of the sales force is planned with new domestic territories and the hiring of an international business development executive.

Dividends and Share Repurchase

• There are no mentions of a declared quarterly dividend or share repurchase in this financial summary.

Conference Call & Future Plans

• A conference call is scheduled for January 9, 2026, at 9:00 AM ET to discuss these results.

• The full, unaudited financial results for Q4 and the year ended December 31, 2025, are expected to be released on February 25, 2026.

Conclusion

ImmuCell has shown resilience in the domestic market with significant growth in Tri-Shield® sales, but faces challenges with international sales and declines in Dual-Force® products. The company remains focused on strategic growth, particularly in its First Defense® product line, amidst ongoing adjustments in operations and asset management.

Condensed Consolidated Statements of Income (in thousands)

---

Condensed Consolidated Balance Sheets (in millions)